Ruthenium Catalyst Cyclization for Epothilone Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing process for preparing 9,10-dehydro-12,13-desoxyepothilone derivatives has limitations in selectivity and yield, necessitating an alternative synthesis method that can be scaled up technically.
Innovation Solution
A novel process involving the cyclization of an olefin-precursor compound in the presence of a Ruthenium catalyst, using an organic solvent and specific reaction conditions, to enhance the selectivity and yield of the cyclization process, thereby producing epothilone derivatives that can be used for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a Grubbs II catalyst is used for cyclization, then the reaction can proceed, but the selectivity and yield are insufficient for technical scale production
Solution Approach 1:
The patent changes the catalyst parameters from Grubbs II (RuCl2(PCy3)2(=CHPh)) to a modified Ruthenium catalyst with different ligands (Formula III: RuCl2(L1)(L2)(=CHAr)) where L1 and L2 are specific phosphine ligands and Ar is a substituted aryl group. This parameter change in catalyst structure improves both selectivity and yield for technical scale production
Solution Approach 2:
The patent employs a catalyst that can be used in lower quantities (0.1-5 mol%) and provides better efficiency, making the process more economical for large-scale production compared to the Grubbs II catalyst which requires higher loading and gives lower yields
2Ease of manufacture
If the existing synthesis process is used, then epothilone derivatives can be prepared, but the process is not feasible on technical scale due to low selectivity and yield
Solution Approach 1:
The patent modifies reaction parameters including catalyst structure (Formula III with specific phosphine ligands L1 and L2), solvent type (toluene, dichloromethane, or chloroform), and temperature (reflux conditions). These parameter changes make the process feasible for technical scale production by improving both yield and selectivity
Solution Approach 2:
The patent uses a composite catalyst system comprising Ruthenium center with specific phosphine ligands (Formula III) that combines electronic and steric properties to achieve high selectivity and yield, making the synthesis feasible on technical scale
3Ease of manufacture
If the existing synthesis process is used, then epothilone derivatives can be prepared, but the process is not feasible on technical scale due to low selectivity
Solution Approach 1:
The patent changes the catalyst parameters to Formula III with specific phosphine ligands (L1 = P(tBu)3, L2 = PCy3 or similar combinations) and optimized reaction conditions (reflux in toluene/dichloromethane/chloroform). These parameter changes significantly improve selectivity while maintaining feasibility for technical scale production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process significantly improves the selectivity and yield of the cyclization reaction, making it feasible on a technical scale and producing promising anticancer agents effective against tumor cells, including multidrug-resistant cancer cell lines.
Implementation Method 1
reacting an olefin-precursor compound of formula II in the presence of an organic solvent and a Ruthenium catalyst of formula III
Data Source
AI summary
The invention comprises a novel process for the preparation of an epothilone derivative of formula I:wherein R1 and R2 independently from each other represent hydrogen or protecting groups and R3 is methyl or trifluoromethyl, which are useful precursors in the synthesis of the desoxyepothilone derivatives of the formula IV:wherein R3 is methyl or trifluoromethyl.The desoxepothilones of formula IV inhibit the growth of tumor cells and are therefore promising candidates for novel anticancer agents.